Aclarion, Inc. is a commercial-stage healthcare technology company leveraging Magnetic Resonance Spectroscopy (MRS), proprietary biomarkers, and augmented intelligence (AI) algorithms to optimize clinical treatments for chronic low back pain. Its core SaaS platform, Nociscan, non-invasively helps physicians distinguish between painful and non-painful discs in the lumbar spine. While the company is demonstrating explosive early-stage adoption—highlighted by a 196% year-over-year increase in Nociscan scan volumes in Q1 2026—it remains in a pre-commercial/early-commercial phase with minimal trailing twelve-month revenues ($77.88K) and substantial operating losses. However, with a strengthened balance sheet showing $19.0 million in cash and no debt as of March 31, 2026, Aclarion has secured a cash runway extending into the second half of 2027 (and potentially into 2028). This capital buffer fully funds the company through its most critical upcoming catalyst: the interim clinical readout of its 300-patient CLARITY trial in late 2026. Given the high-risk, high-reward nature of early-stage medtech validation, a 'Hold' recommendation is advised until clinical efficacy and sustainable U.S. reimbursement pathways are firmly established.